2011
D.R. Spahn, W. Korte Novel oral anticoagulants: New challenges for anesthesiologists in bleeding patients Anesthesiology,
in press  
L.M. Asmis, L. Alberio,
A. Angelillo-Scherrer,
W. Korte, A. Mendez,
G. Reber, B. Seifert,
H. Stricker, D.A. Tsakiris,
W.A. Wuillemin		 Rivaroxaban: Quantification by anti-FXa assay influence on coagulation tests. A study in 9 Swiss laboratories Thrombosis Research,
in press
C. Thelwel, et al. An international collaborative study to establish the WHO 1st international standards for C1-inhibitor, plasma and concentrate Journal of Thrombosis and Haemostasis
9 (10), 2097-2099 (2011)
T. Haas, W. Korte,
N. Spielmann, J. Mauch,
C. Madjdpour,
M. Schmugge, M. Weiss		 Perioperative course of FXIII in children undergoing major surgery Pediatric Anesthesia
Sep 20 (2011)
doi: 10.1111/j.1460-9592.2011.03709.x.
M. Nagler, P. Erne, R. Babst, W. Korte, W.A. Wuillemin Periinterventionelles Management der Antikoagulation und Antiaggregation Schweizerisches Medizin Forum
11 (23-24), 407-412 (2011)
W. Korte, M. Cattaneo,
P.-G. Chassot, S. Eichinger,
Ch. von Heymann,
N. Hofmann, H. Rickli,
M. Spannagl, B. Ziegler,
F. Verheugt, K. Huber		 Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC) Thrombosis and Haemostasis
105 (5), 743-749 (2011)
D. Spirk, J. Ugi, W. Korte,
M. Husmann, D. Hayoz,
Th. Baldi, B. Frauchiger,
M. Banyai, D. Aujesky,
I. Baumgartner, N. Kucher		 Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II Thrombosis and Haemostasis
105 (6), 962-967 (2011)
A. Hegglin, O.D. Schoch,
W. Korte, K. Hahn,
Ch. Hürny, T. Münzer		 Eight months of continuous positive airway pressure (CPAP) decrease tumor necrosis factor alpha (TNFA) in men with obstructive sleep apnea syndrom Sleep and Breathing,
30 March (2011)
doi: 10.1007/s11325-011-0512-2
M. Gregor, M. Bargetzi,
M.A. Duchosal, J.S. Goede,
D. Heim, C. Helg, W. Korte,
L. Leoncini, M. Solenthaler,
R. Zenhäusern		 Empfehlungen für Diagnose und Behandlung der chronischen lymphatischen Leukämie in der Schweiz
Teil 1: Diagnose, Staging und Prognosefaktoren
Teil 2: Therapieindikationen und Therapiestrategien		 Schweizerisches Medizin Forum

11 (6), 93-97 (2011)
11 (7), 118-124 (2011)
2010
P. Weisser, W. Korte,
S. Rohr. E. Kiossis,
W. Riesen, R. Stolla		 "Hereditäre Thrombozytopathie Simmentaler Rinder" (HTS) beim Deutschen Fleckvie Der praktische Tierarzt
91 (3), 236-244 (2010)
W. Korte, R. Jovic,
M. Hollenstein,
P. Degiacomi, M. Gautschi,
A. Ferrández		 The uncalibrated prothrombinase-induces clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin. Hämostaseologie
30 (4), 212-216 (2010)
O.P. Gautschi, M.N. Gallay,
T.T. Kress. W.C. Korte,
G. Hildebrandt		 Chronisches Subduralhämatom - Beurteilung und Management Praxis
99 (21), 1269-1277 (2010)
W. Streif, M. Oliveri,
S. Weickardt, W. Eberl, R. Knoefler; Thromkid Study Group of GTH		 Testing for inherited platelet defects in clinical laboratories in Germany, Austria, and Switzerland. Results of a survey carried out by the permanent paediatric group of the German Thrombosis and Haemostasis Research Society (GTH). Platelets
21 (6), 470-478 (2010)
N. Xia, A. Daiber,
A. Habermeier, E.I. Closs,
T. Thum, G. Spanier, Q. Lu,
M. Oelze, M. Torzewski,
K.J. Lackner, T. Münzel,
U. Förstermann, H. Li		 Resveratrol reverses eNOS (endothelial nitric-oxide synthase) uncoupling in apolipoprotein E knockout mice Journal of Pharmacology and Experimental Therapeutics
335 (1), 149-154 (2010)
W. Korte Rivaroxaban und Dabigatran - Zwei neue orale Antikoagulanzien Cardiovasc
3 (9), 13-17 (2010)
A. Gähler, W. Korte Anämien - die ersten Schritte in der Differentialdiagnose Therapeutische Umschau
67 (5), 213-218 (2010)
T. Münzer, A. Hegglin,
T. Stannek, O.D. Schoch,
W. Korte, D. Büche,
Ch. Schmid, Ch. Hürny		 Effects of long-term continuous positive airway pressure on body composition and IGF1 European Journal of Endocrinology
162, 695-704 (2010)
C. Valmaggia, W. Korte Intraocular haemorrhages in von Willebrand's disease Klinisches Monatsblatt Augenheilkunde
227 (4), 345-346 (2010)
H. Ryffel, H. Engler,
W.F. Riesen		 Urindiagnostik per Teststreifen und mikroskopischer Sedimentuntersuchung Hausarzt Praxis
2, 18-20 (2010)
D.R. Altmann, W. Korte,
M.T. Maeder, T. Fehr,
P. Haager, H. Rickli,
G.-R. Kleger, R. Rodriguez,
P. Ammann		 Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis PloS ONE
5 (2), e9017. doi:10.1371/
journal.pone.0009017
W. Korte F XIII in perioperative coagulation management Best Practice & Research Clinical Anaesthesiology
24, 85-93 (2010)
M. Joerger, A. Templeton,
D. Köberle, H. Engler,
W.F. Riesen, B. Thürlimann		 Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates Cancer Chemotherapy and Pharmacology
doi:10.1007/s00280-010-1420-z
N. Kucher, D. Spirk,
I. Baumgartner, L. Mazzolai,
W. Korte, D. Nobel,
M. Banyai, H. Bounameaux		 Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER) Annals of Oncology,
21 (5), 931-935 (2010)
M.T. Maeder, P. Ammann,
O.D. Schoch, H. Rickli,
W. Korte, C. Hürny, J. Myers,
T. Münzer		 Determinants of postexercise heart rate recovery in patients with the obstructive sleep apnea syndrome Chest
137 (2), 310-317 (2010)
2009

K. Reifenberg, H.A. Lehr,
J. Fan, T. Koike, E. Wiese,
I. Küpper, T.A. Sagban,
S.C. Schäfer, U. Zähringer,
M. Torzewski, K.J. Lackner,
S. Bhakdi

 Endotoxin accelerates atherosclerosis independent of complement activation Thrombosis Research
123 (4), 653-658 (2009)

M. Torzewski, B. Navarro,
F. Cheng, A. Canisius,
T. Schmidt, S. Bhakdi,
R. Urban, K.J. Lackner

 Investigation of Sudan IV staining areas in aortas of infants and children: Possible prelesional stages of atherogenesis Atherosclerosis
206 (1), 159-167 (2009)

A. Daiber, M. Oelze,
P. Wenzel,
J.M. Wickramanayake,
S. Schuhmacher, T. Jansen,
K.J. Lackner, M. Torzewski,
T. Münzel

 Nitrate tolerance as a model of vascular dysfunction: role of mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress Pharmacological Reports
61 (6), 33-48 (2009)

C. Ostrau, J. Hülsenbeck,
M. Herzog, A. Schad,
M. Torzewski, K.J. Lackner,
G. Fritz

 Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo Radiotherapy & Oncology
92 (3), 492-499 (2009)

F. Luessi, J. Sollors,
M. Torzewski, H.D. Müller,
E. Siegel, J. Blum,
C. Sommer, T. Vogt,
F. Thömke

 Eosinophilic meningitis due to antiostrongylus cantonensis in Germany Journal of Travel Medicine
16 (4), 292-294 (2009)

W. Korte, L. Mazzolai,
H. Bounameaux

 8e ACCP guidelines on antithrombotic therapy Forum Médical Suisse
9 (25), 454 (2009)

M.T. Maeder, P. Ammann,
T. Münzer, O.D. Schoch,
W. Korte, C. Hürny, J. Myers,
H. Rickli

 Continuous positive airway pressure improves exercise capacity and heart rate recovery in obstructive sleep apnea International Journal of Cardiology
132 (1), 75-83 (2009)

W. Korte, Ch. Szadkowski,
A. Gähler, K. Gabi,
E. Kownacki, M. Eder,
P. Degiacomi, N. Zoller,
J. Devay, J. Lange,
T. Schnider

 Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding Anesthesiology
110 (2), 239-245 (2009)
H. Engler, W. Korte, L. Graf,
W.F. Riesen		 Labor-Diagnostik des Eisenstoffwechsels Hausarzt Praxis
13, 16-18 (2009)
L. Graf, W. Korte Die Therapie im Zeitalter der intravenösen Präparate Hausarzt Praxis
13, 12-14 (2009)
L. Graf, W. Korte Zu wenig Hämoglobin, (zu) viele Möglichkeiten Hausarzt Praxis
13, 8-11 (2009)
C. Jámbor, V. Reul,
T.W. Schnider,
P. Degiacomi,  H. Metzner,
W. Korte		 In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood Anesthesia & Analgesia
109, 1023-1028 (2009)
C. Jámbor, V. Lesch,
T.W. Schnider,
G. Kreienbühl,
W. Korte		 Fresh frozen plasma in ineffective for reversal of coagulation factor dilution in an in vitro model Applied Cardiopulmonary Pathophysiology
13, 130-133 (2009)
2008
W. Korte Perioperatives Hämostase-Management Hämostaseologie
28 (5), 449-454 (2008)
L. Graf, R. Herklotz,
A.R. Huber, W. Korte		 Alte und neue Eisenparameter - Bedeutung im Eisenstoffwechsel und in der Diagnostik Therapeutische Umschau
65 (9), 519-528 (2008)
P. Debourdeau, I. Elalamy, A. de Raignac, P. Meria,
J.M. Gornet, Y. Amah,
W. Korte, M. Marty, D. Farge		 Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Supportive Care in Cancer
16 (12), 1333-1341 (2008)
S. Dunoyer-Geindre,
F. Boehlen, R. Favier,
D. Wahl, J. Musial, W. Korte,
N. Satta, E. Kruithof,
P. de Moerloose		 Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome Haematologica
93 (4), 635-636 (2008)
W.F. Riesen, G. Noll,
R. Darioli		 Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia Swiss Medical Weekly
138 (29-30), 420-426 (2008)
W.F. Riesen, R.C. Mordasini Update der lipidsenkenden Therapie Praxis
97, 1179-1184 (2008)
W.F. Riesen, M. Hug Tiefes HDL - hohes Risiko, hohes HDL - tiefes Risiko? Schweizerisches Medizin-Forum
8 (14), 246-252 (2008)
P. Debourdeau, I. Elalamy,
A. de Raignac, P. Meria,
J.M. Gornet, Y. Amah,
W. Korte, M. Marty, D. Farge		 Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer
16 (12), 1333-1341 (2008)
L. Graf, R. Herklotz,
A.R. Huber, W. Korte		 Alte und neue Eisenparameter: Bedeutung im Eisenstoffwechsel und in der Diagnostik Therapeutische Umschau
65 (9), 519-528 (2008)
M.T. Maeder, P. Ammann,
H. Rickli, O.D. Schoch,
W. Korte, C. Hürny,
J. Myers, T. Münzer		 N-terminal-pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea Sleep and Breathing
12 (1), 7-16 (2008)
W. Korte Cancer and thrombosis: an increasingly important association Supportive Care in Cancer
16 (3), 223-228 (2008)
W. Korte, H. Engler,
E. Aldebert, W. Riesen		 Heparinized blood provides equivalent results to EDTA in the CEDIA and FPIA cyclosporine immunoassays, thus facilitating routine Cyclosporine determination Clinica Chimica Acta
390 (1-2), 138-140 (2008)
W. Korte, L. Graf Burn injuries - is antithrombin back on stage in critical care? Thrombosis & Haemostasis
100 (2), 177-178 (2008)
M.T. Maeder, T. Münzer,
H. Rickli, O.D. Schoch,
W. Korte, C. Hürny,
P. Ammann		 Association between heart rate recovery and severity
of obstructive sleep apnea syndrome		 Sleep Medicine
9 (7), 753-761 (2008)
W. Korte Perioperative Gerinnungsstörungen, perioperatives Gerinnungsmanagement Hämostaseologie
28, 449-454 (2008)
2007
N. Rodondi, P. Yerly,
A. Gabriel, W.F. Riesen,
M. Burnier, F. Paccaud,
P. Bovet		 Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults Nephrology Dialysis Transplantation
22 (4), 1107-1114 (2007)
C.E. Dempfle, D. Gulba,
C.M. Kirchmaier,
R. Klamroth, W. Korte,
R. Lorenz, M. Peck-Radosavljevic, A. Veldman, R.B. Zotz		 Klinische Bewertung potentieller Einsatzbereiche von rekombinantem Faktor VIIa bei internistischen und pädiatrischen Erkrankungen. Empfehlungen einer Expertengruppe. Medizinische Klinik
102 (1), 70-81 (2007)
T. Wolber, M. Maeder,
H. Rickli, W. Riesen,
C. Binggeli, F. Duru,
P. Ammann		 N-terminal pro-brain natriuretic peptide used for the prediciton of coronary artery stenosis European Journal of Clinical Investigation
37, 18-25 (2007)
K. Stoffe, H. Engler,
M. Kuster, W. Riesen		 Changes in biochemical markers after lower limb fractures Clinical Chemistry
53 (1), 131-134 (2007)
W. Korte Editorial comment on: "The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy" by Vincent et al. Support Care Cancer
15 (3), 239-241 (2007)
S. Gillessen, L. Graf,
W. Korte, T. Cerny		 Macrocytosis and cobalamin deficiency in patients treated with Sunitinib New England Journal of Medicine
356 (22), 2330-2331 (2007)
N. Seeholzer, B. Thürlimann, D. Köberle, D. Hess,
W. Korte		 Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study Blood, Coagulation & Fibrinolysis
18, 415-423 (2007)
W. Korte, S. Moor Near fatal hemorrhage in traumatic bilateral leg amputation with coagulopathy, acidosis and hypothermia and salvage therapy with recombinant factor VIIa Journal of Trauma-Injury Infection & Critical Care
63 (1): E1-E4 (2007)
W.F. Riesen CETP-Inhibitoren (Torcetrapib und JTT-705) Kardiovaskuläre Medizin
10, 285-295 (2007)
W. Korte Diabetes und Hyperkoagulabilität Diabetes und Stoffwechsel,
4, 30 (2007)
W.F. Riesen Pleiotrope Effekte der Statine Ars Medici
16, 789-793 (2007)
M. Romanens, A.R. Miserez, F. Ackermann, W. Riesen, J.D. Spence, R. Darioli Imaging as a cardiovascular risk modifier in primary care patients using predictor models of the European and international atherosclerosis society Kardiovaskuläre Medizin
10, 139-150 (2007)
2006
W. Korte, I. Heijnen Paroxysmale nächtliche Hämoglobinurie - Folge eines fehlenden Ankers Therapeutische Umschau
63, 71-77 (2006)
L. Anderson, I. Quasim,
R. Soutar, M. Steven,
A. Macfie, W. Korte		 An audit of red cell and blood product use after institution of thromboelastometry in a cardiac intensive care unit Transfusion Medicine
16 (1), 31-39 (2006)
W.F. Riesen Trockenchemie einfach und zuverlässig oder einfach unzuverlässig Hausarzt Praxis
1, 32-33 (2006)
W.F. Riesen Current perspectives in lipid lowering strategies In: Cont. Perspect. on Clin. Pharmacotherapeutics, K. Kohli, M. Gupta Eds. Elsevier
268-281 (2006)
F. Hermann, L.E. Spieker,
F. Ruschitzka, I. Sudano,
M. Hermann, C. Binggeli,
T.F. Lüscher, W. Riesen,
G. Noll, R. Corti		 Dark chocolate improves endothelial and platelet function Heart
92, 119-120 (2006)
W.F. Riesen Statins, are they all the same? Current Drug Therapy
1, 157-172 (2006)
C.E. Dempfle, W. Korte,
M. Schwab, R. Zerback,
M.V. Huisman (on behalf of the CARDIM study group)		 Sensitivity and specificity of a quantitative point of care D-dimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis Thrombosis and Haemostasis
96 (1), 79-83 (2006)
W. Korte Behandlung der Blutung unter Antikoagulation Therapeutische Umschau
63 (5), 345-353 (2006)
W. Korte Fibrin Monomer und Faktor XIII: ein neues Konzept bei unerklärter intraoperativer Blutungsneigung Hämostaseologie
26 (3 Suppl 1), 30-35 (2006)
W. Korte, P. Innerhofer,
M. Spannagl		 Editorial Hämostaseologie
26 (3 Suppl 1), 30-35 (2006)
W.F. Riesen Aktuelles zur lipidregulierenden Therapie Hospitalis
7-8, 211-213 (2006)
M. Schlaeppi, W. Korte,
R. von Moos, T. Cerny,
S. Gillessen		 Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma Onkologie
29, 531-533 (2006)
W.F. Riesen, R.C. Mordasini, St. Münnich Lipidosen (Lipidspeicherkrankheiten) Schwandt, Parhofer, "Handbuch der Fettstoffwechselstörungen", 3. Auflage, Dezember (2006)
2005
F. Hermann, A. Forster,
R. Chenevard, F. Enseleit,
D. Hürlimann, R. Corti,
L.E. Spieker, D. Frey,
M. Hermann, W. Riesen,
M. Neidhart, B.A. Michel,
J.P. Hellermann, R.E. Gay,
T.F. Lüscher, S. Gay,
G. Noll, F. Ruschitzka		 Simvastatin improves endothelial function in patients with rheumatoid arthritis Journal of the American College of Cardiology
45 (3), 461,464 (2005)
T.D. Szucs, A. Käser,
W.F. Riesen		 Economic impact of hyperhomocysteinemia in Switzerland Cardiovascular Drugs and Therapy, 19 (5), 365-369 (2005)
J. Lüthy Simonett, W. Korte, A. Tyndall Familiäres-Mittelmeer-Fieber-Gen R761H: eine seltene Mutation Schweiz. Med. Forum
5, 205-206 (2005)
A. Lugli, M. Ebnöther,
S.B. Cogliatti, A. Gratwohl,
J. Passweg, U. Hess,
W. Korte, H. Hawle,
M. Tinguely, B. Borisch,
S. Mach-Pascual,
S. Von Juergensonn,
A. Tichelli, S. Dirnhofer		 Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia Human Pathology
36 (1), 91-100 (2005)
W.A. Wuillemin, W. Korte,
G. Waser, B. Lämmle		 Usefulness of the D-dimer/fibrinogen ratio to predict deep venous thrombosis Journal of Thrombosis and Haemostasis
3 (2), 385-387, (2005)
L. Graf, W. Korte, L. Schmid,
U. Schmid, S.B. Cogliatti		 Impact of aspirate smears and trephine biopsies in routine bone marrow diagnostics: a comparative study of 141 cases. Swiss Medical Weekly
135(9-10), 151-159 (2005)
W. Korte, K. Gabi,
M. Rohner, A. Gähler,
C. Szadkowski,
T. Schnider, J. Lange,
W. Riesen		 Preoperative fibrin monomer measurement allows risk stratification for high intraoperative blood loss in elective surgery Thrombosis and Haemostasis
94, 211-215 (2005)
W.F. Riesen, R. Darioli,
G. Noseda, O. Bertel,
P. Buser		 Empfehlungen zur Prävention der Atherosklerose Schweiz. Ärztezeitung
86 (22), 1355-1361 (2005)
W.F. Riesen Therapeutische Optionen zur LDL-Cholesterinsenkung: Je tiefer, desto besser? Cardiovasc
3, 19-24 (2005)
L. Wuermli, M. Joerger,
S. Henz, H.P. Schmid,
W.F. Riesen, G. Thomas,
W. Krek, T. Cerny,
S. Gillessen		 Hypertriglyceridemia as a possible risk factor for prostate cancer Prostate Cancer and Prostatic Diseases
8, 316-320 (2005)
W.F. Riesen Niaspan, der Breitband-Lipidmodulator. Nicht nur LDL senken, auch HDL erhöhen! Cardiovasc
Sonderdruck, 2-4 (2005)
G. Assmann, P. Cullen,
J.-Ch. Fruchart, H. Greten,
M. Naruszewicz, A. Olsson,
R. Paoletti, W. Riesen,
M. Stoll, M. Tikkanen,
A. von Eckardstein,
for the International Task Force for Prevention of Coronary Heart Disease		 Implications of emerging risk factors for therapeutic intervention Nutrition, Metabolism & Cardiovascular Diseases
15, 373-381 (2005)
W.F. Riesen, R.C. Mordasini Das Alter ist kein Grund, auf Statine zu verzichten Geriatrie Praxis
11-12, 18-22 (2005)
W.F. Riesen, G. Noseda Update der lipidmodulierenden Therapie Kardiovaskuläre Medizin
8, 435-447 (2005)
2004
H. Rickli, K. Benou,
P. Ammann, T. Fehr,
H.P. Brunner-La Rocca,
H. Petridis, W. Riesen,
R.P. Wüthrich		 Time course of serial Cystatin C levels in comparison with serum creatinine after application of radiocontrast media Clin. Nephrology
61, 98-102 (2004)
W.F. Riesen, R. Darioli,
G. Noll		 Lipid-lowering therapy: strategies for improving compliance Current Medical Research and Opinion
20, 2, 165-173 (2004)
W.F. Riesen Empfehlungen zur Abklärung und Behandlung von Lipidstörungen Journal für Menopause
1, 30-35 (2004)
W. Korte Venöse Thrombosen und Thrombophilie. Wann sind welche Abklärungen indiziert? Cardiovasc
1, 24-27 (2004)
W. Korte, W. Wuillemin,
C. Caliezi, W. Riesen		 CRP measured by a high sensitivity assay correlates with clinical probability (Wells score) testing for deep venous thrombosis Thrombosis & Haemostasis
91, 841-842 (2004)
W. Korte, S.B. Cogliatti Neues und Altes zur chronischen lymphatischen Leukämie Therapeutische Umschau
61 (2), 151-156 (2004)
A. Gähler, S.B. Cogliatti,
W. Korte		 Differentialdiagnose der absoluten Lymphozytose Therapeutische Umschau
61 (2), 157-160 (2004)
U. Lüthi, L. Risch, W. Korte,
M. Bader, A.R. Huber		 Telehematology: critical determinants for successful implementation Blood
103, 486-488 (2004)
W. Korte, W. Riesen, Redaktionsausschuss der Taskforce Emerging risk Factors der AGLA der Schweiz. Gesellschaft für Kardiologie Hämostatische Risikofaktoren für kardiovaskuläre Krankheiten: D-Dimer Kardiovaskuläre Medizin
7, 78-80 (2004)
S. Raasi, W.P. Mielicki,
S.G. Gordon, W. Korte		 Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies Archives of Biochemistry and Biophysics
428 (2), 131-135 (2004)
T. Fehr, P. Ammann,
D. Garzoni, W. Korte,
W. Fierz, H. Rickli,
R.P. Wüthrich		 Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia Kidney International
66 (3), 1206-1211 (2004)
P. Wettstein, A. Haeberli,
M. Stutz, M. Rohner,
C. Corbetta, C. Gabi,
T. Schnider, W. Korte		 Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding Anesthesia & Analgesia
99 (5), 1564-1569 (2004)
P. Ammann, I. Bluzaite,
H. Roelli, W. Korte, H. Rickli, J. Brazdzionyte, G. Urbona-
vicience, R. Zaliunas		 Correlation of QT Dispersion after Exercise Stress-Test with Coronary Artery Disease Eletronika ir Elektrotechnika
2 (51), 78-81 (2004)
H.-P. Schmid, W. Riesen,
L. Prikler		 Update on screening for prostate cancer with prostate-specific antigen Oncology/Hematology
50, 71-78 (2004)
T. Fehr, Ch. Kahlert,
W. Fierz, H.I. Joller-Jemelka,
W.F. Riesen, H. Rickli,
R.P. Wüthrich, P. Ammann		 Statin-induced immunomodulatory effects on human T cells in vivo Atherosclerosis
175, 83-90 (2004)
E. Battegay, R. Darioli,
Ch. Graf, A.R. Miserez,
W. Riesen, B. Saner,
G. Schulthess		 Standortbestimmung bei "emerging" kardiovaskulären Risikofaktoren Kardiovaskuläre Medizin
7, 7-9 (2004)
F. Gutzwiller, E. Battegay,
M. Burnier, J. Carrel,
P. Diem, R. Gaillard,
P. Greminger, J. Lareida,
F. Muggli, G. Noll, J. Philipp, W.F. Riesen, G.A. Spinas		 Vorschläge einer interdisziplinären Arbeitsgruppe zur Diagnostik und Therapie des metabolischen Syndroms Sonderbeilage, Schweiz. Ärztezeitung (2004)
A. Malzacher, H. Engler,
W.F. Riesen		 Lithium-Intoxikation oder Laborfehler? Pipette
4, 10-12 (2004)
W.F. Riesen How much is too much? Assessment of risk for cardiovascular disease Bulletin Société Luxembour-geoise de Biologie Clinique
III, 56-59 (2004)
2003
M. Christ-Crain, Ch. Meier, Merih Guglielmetti,
P.R. Huber, W. Riesen,
J.-J. Staub, B. Müller		 Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial Atherosclerosis
166, 379-386 (2003)
M. Maurer, W. Riesen,
J. Muser, H.N. Hulter,
R. Krapf		 Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans Am J Physiol Renal Physiol
284, F32-F40 (2003)
W. Korte, J. Greiner PARKAA paves the way (Editorial) Thrombosis and Haemostasis 90, 1-2 (2003)
W.F. Riesen Lipoproteinveränderungen bei Nierenerkrankungen Cardiovasc
1, 37-39 (2003)
W.F. Riesen Folsäure und kardiovaskuläres Risiko GanzheitsMedizin
15, 7 (2003)
W.F. Riesen Tumormarker und ihre Bedeutung PraxisArena
3, 4-11 (2003)
R. Chenevard,
D. Hürlimann, M. Béchir,
F. Enseleit, L. Spieker,
M. Hermann, W. Riesen,
St. Gay, R. Gay, M. Neidhart, B. Michel, T.F. Lüscher,
G. Noll, F. Ruschitzka		 Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation
107, r15-r19 (2003)
A. Gähler, F. Hitz, U. Hess,
T. Cerny		 Acute Pericarditis and Pleural Effusion Complicating Cytarabine Chemotherapy Onkologie
26, 348-350 (2003)
W. Korte Diabetes und seine Hämostase-Risikofaktoren. Warum die Diabetes-assoziierte Hyperkoagulabilität so häufig ist. Cardiovasc
6, 23-29 (2003)
2002
W.F. Riesen Homocystein und Atherothrombose Cardiovasc
1, 23-27 (2002)
F. Goti, W. Korte, D. Sege Repetitive intraoperative use of recombinant hirudin (Lepirudin) in peripheral vascular surgery Swiss Medical Weekly
132, 693-694 (2002)
F. Goti, W. Korte,
D. Gianom, M. Decurtins		 Heparin "hitts" again. Acute thrombocytopenia caused by the erroneous re-exposition with a low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombosis (HITT) European Journal of Clinical Pharmacology
57, 917-918 (2002)
N. Rodondi, R. Darioli,
A.-A. Ramelet, D. Hohl,
V. Lenain, J. Perdrix,
V. Wietlisbach, W.F. Riesen,
T. Walther, L. Medinger,
P. Nicod, B. Desvergne,
V. Mooser		 High Risk for Hyperlipidemia and the Metabolic Syndrome after an Episode of Hypertriglyceridemia during 13-cis Retinoic Acid Therapy for Acne: A Pharmacogenetic Study Annals of Internal Medicine
8, 582-589 (2002)
W.F. Riesen, H. Engler,
M. Risch, W. Korte,
G. Noseda		 Short term effects of Atorvastatin on C-reactive Protein European Heart Journal
23, 794-799 (2002)
W.F. Riesen, H. Engler,
W. Korte, G. Noseda		 Short Term Effects of Atorvastatin on Coagulation and Inflammation In: G.M. Kostner, K.M. Kostner, B. Kostner, editors. Atherosclerosis: Risk Factors, Diagnosis, and Treatment. 73rd EAS Congress, Salzburg, Austria, July 7-10, 2002. Bologna: Monduzzi, 255-260 (2002)
W.F. Riesen The current view of hypercholesterolemia after the "Heart Protection Study" – do we need new strategies? Heartdrug
2, 201-203 (2002)
W. Riesen, M. Hug Pré-analytique: à l'exemple des dosages lipidiques – quelques notions importantes pour le praticien Médecine & Hygiène
60, S7-S8 (2002)
W.F. Riesen Wirksamkeit, Kosteneffektivität und Sicherheit der Statintherapie Cardiovasc
5, 25-29 (2002)
2001
M. Depairon, S. Chessex,
P. Sudre, N. Rodondi,
N. Doser, J.-P. Chave,
W. Riesen, P. Nicod,
R. Darioli, A. Telenti,
V. Mooser		 Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy AIDS
15, 329-334 (2001)
N. Fünfsinn, C. Caliezi,
F. Demarmels Biasutti,
W. Korte, A. Z'Brun,
I. Baumgartner, M. Ulrich,
C. Cottier, B. Lämmle,
W.A. Wuillemin		 Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatients Blood Coagulation and Fibrinolysis
12, 1-6 (2001)
F. Goti, D. Gianom,
W. Korte, D. Sege,
M. Decurtins		 Postoperative Heparin-induzierte Thrombopenie mit Thromboembolie (HITT): eine seltene Komplikation der Heparintherapie? Swiss Surgery
7, 51-56 (2001)
C. E. Dempfle, M. Schraml,
I. Besenthal, R. Hansen,
J. Gehrke, W. Korte,
M. Risch, P. Quehrenberger,
S. Handler, E. Minar,
I. Schulz, R. Zerback		 Multicentre evaluation of a new point-of-care test for the quantitative determination of D-dimer Clinica Chimica Acta
307, 211-218 (2001)
W. Korte, W.F. Riesen Genetische Tumormarker Abbott Times
11, 8-17 (2001)
W.F. Riesen Hyperlipidämie und metabolisches Syndrom. Oder: Ein Übel kommt selten allein ArsMedici
20, 971-974 (2001)
W.F. Riesen Risiko Schlaganfall – Welche Rolle spielen Homocystein und Fibrinogen? Cardiovasc
4, 38-40 (2001)
W.F. Riesen Primärprävention der KHK mit Statinen - Wirksamkeit, Kosteneffektivität und Sicherheit Cardiovasc
6, 18-20 (2001)
W.F. Riesen Folsäure und kardiovaskuläres Risiko GanzheitsMedizin
4, 196-197 (2001)
W. Korte, J. Greiner,
A. Feldges, W.F. Riesen		 Increased Lp(a) levels are not a steady prothrombotic defect (letter) Blood
98, 1993-1994, 2001
R. Lehmann, H. Engler,
R. Honegger, W. Riesen,
G.A. Spinas		 Alterations of lipolytic enzymes and high-density lipoprotein subfractions induced by physical activity in type 2 diabetes mellitus European Journal of Clinical Investigation
31, 37-44 (2001)
W. Korte, W.F. Riesen Comparability of serum and plasma concentrations of haemostasis activation markers Clinical Chemistry and Laboratory Medicine
39, 627-630 (2001)
F. Goti, W. Korte, D. Sege Repetitive intraoperative use of recombinant hirudin (Lepirudin) in peripheral vascular surgery with HITT Swiss Medical Weekly
131, 693-694 (2001)
2000
W. Korte, S. Clarke,
J. Lefkowitz		 Short activated partial thromboplastin times (APTT), a common laboratory finding, are related to increased thrombin generation and an increased risk for thromboembolism American Journal of Clinical Pathology
113, 123-127 (2000)
W.F. Riesen Effects of estrogens on atherosclerosis Labolife
2, 11-13 (2000)
W.F. Riesen Nouveaux facteurs de risque cardiovasculaire Médecine & Hygiène
58, 606-611 (2000)
W. Korte, S.B. Cogliatti,
K. Jung, W. Riesen		 Mild renal dysfunction is sufficient to induce erythropoietin deficiency in patients with unexplained anaemia Clinica Chimica Acta
292, 149-154 (2000)
W.F. Riesen Behandlung der Hyperlipidämie mit Statin - mehr als Cholesterinsenkung? Medizinspiegel
1, 25-28 (2000)
M. Nauck, M.S. Graziani,
J. Jarausch, D. Bruton,
Ch. Cobbaert, T. Cole,
F. Colella, F. Lefevre,
Ph. Gillery, B. Haas, T. Law,
M. König, M. Macke,
W. März, C. Meier,
W. Riesen, M. van Vliet,
H. Wieland, N. Rifai		 A new liquid homogeneous assay for HDL cholesterol determination evaluated in seven laboratories in Europe and the United States Clinical Chemistry and Laboratory Medicine
37, 1067-1076 (2000)
C. Hock, K. Heese,
F. Müller-Spahn, P. Huber,
W. Riesen, R.M. Nitsch,
U. Otten		 Increased CSF levels of nerve growth factor in patients with Alzheimer's disease Neurology
54, 2009-2011 (2000)
W.F. Riesen Hyperlipoproteinämien und Fettstoffwechseldiagnostik Kardiovaskuläre Medizin
3, 155-161 (2000)
G. Noseda, R. Darioli,
U. Keller, R. Mordasini,
A. Shokry, B. Schaffhauser,
W. Riesen		 Prüfung der Wirksamkeit und Verträglichkeit von Atorvastatin bie Hyperlipidämie unter Praxisbedingungen Schweiz. Med. Wochenschrift
130, 889-895 (2000)
W. Korte Antikoagulation bei onkologischen Patienten - praktische Überlegungen Labolife
3, 5-7 (2000)
W. Korte, W. Riesen Latex-enhanced immunoturbidimetry allows D-Dimer determination in plasma and serum samples Clinical Chemistry
46, 871-872 (2000)
C. Hock, K. Heese,
F. Müller-Spahn, P. Huber,
W. Riesen, R.M. Nitsch,
U. Otten		 Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression Molecular Psychiatry
5, 510-513 (2000)
A. Henger, P. Tutt,
W.F. Riesen, H.N. Hulter,
R. Krapf		 Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients J Lab Clin Med
5, 379-389 (2000)
D. L'Allemand, U. Eiholzer,
M. Schlumpf, H. Steinert,
W. Riesen		 Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome Eur J Pediatr
159, 835-842 (2000)
W. Korte Changes of the coagulation and fibrinolysis system in malignancy: Their possible impact on future diagnostics and therapeutic procedures Clinical Chemistry and Laboratory Medicine
38, 679-692 (2000)
M. Nauck, M.S. Graziani,
D. Bruton, C. Cobbaert,
T.G. Cole, F. Lefevre,
W. Riesen, P.S. Bachorik,
N. Rifai		 Analytical and clinical performance of a detergent-based homogeneous LDL cholesterol assay: A multicenter evaluation Clinical Chemistry
46, 506-514 (2000)
1999
W.F. Riesen Diagnose und Therapie von Dyslipidämien PraxisArena
1, 4-9 (1999)
Arbeitsgruppe Lipide und Atherosklerose der Schweiz. Gesellschaft für Kardiologie:
E. Battegay, O. Bertel,
R. Darioli, F. Gutzwiller,
U. Keller, R. Mordasini,
C. Nigg, W.F. Riesen 		Empfehlungen 1999 zur Behandlungsindikation des Risikofaktors Cholesterin Schweiz. Ärztezeitung
9, 549-552 (1999)
P. Fontana, V. Mooser,
P. Bovet, C. Shamlaye,
B. Burnand, V. Lenain,
S. Marcovina, W. Riesen,
R. Darioli		 Dose-dependent inverse relationship between alcohol consumption and serum Lp(a) levels in black African males Arteriosclerosis Thrombosis and Vascular Biology
19, 1075-1082 (1999)
W.F. Riesen Screening der Hypercholesterinämie und Behandlungsindikationen Geriatrie Praxis
4, 26-29 (1999)
W.F. Riesen, R.C. Mordasini Diagnose und Therapie akuter koronarer Syndrome PraxisArena
4, 4-9 (1999)
W. Korte, C. Jost,
S. Cogliatti, U. Hess,
T. Cerny		 Accelerated progression of Multiple Myeloma during anti-CD20 (Rituximab) therapy Annals of Oncology
10, 1249-1250 (1999)
H. Engler, R.E. Oettli,
W.F. Riesen		 Biochemical Markers of Bone Turnover in Patients with Thyroid Dysfunctions and in Euthyroid Controls: A Cross-Sectional Study Clinica Chimica Acta
289, 159-172 (1999)
W.F. Riesen Immunologische Aspekte der Atherosklerose Kardiovaskuläre Medizin
2, 474-481 (1999)
1998
W.F. Riesen Cholesterinsenkende Therapie - neue Aspekte bei Schlaganfall und Diabetes Schweiz. Med. Wochenschrift 128, 26-27 (1998)
W.F. Riesen Das metabolische Syndrom Der Arzt und sein Patient
15 (1998)
W. Korte, B. Truttmann,
C. Heim, U. Stangl,
L. Schmid, G. Kreienbühl		 Preoperative values of molecular coagulation markers identify patients at low risk for intraoperative haemostatic disorders and excessive blood loss Clinical Chemistry and Laboratory Medicine
36, 235-240 (1998)
H. Engler, W.F. Riesen Effect of thyroid hormones on Lp(a) and lipid metabolism Clinical Chemistry and Laboratory Medicine
36, 9, 731-735 (1998)
W. Korte Antikoagulation bei Patienten mit fortgeschrittenen Tumorerkrankungen INFO kara
3, 20-23 (1998)
W.F. Riesen Apolipoprotein E - ein Protein mit zunehmender biologischer und klinischer Bedeutung Labolife
3, 15-18 (1998)
H. Engler, D. Köberle,
B. Thürlimann,
H.-J. Senn, W.F. Riesen		 Diagnostic and prognostic value of biochemical markers in malignant bone disease: A prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease Clinical Chemistry and Laboratory Medicine
36, 879-885 (1998)
W. Korte, S. Lutz Reliability and relevance of a protein C pathway screening assay in patients evaluated for hypercoagulability Journal of Laboratory Medicine
22, 599-606 (1998)
W.F. Riesen Why do women have a better chance for longevity than man? Labolife
6, 11-14 (1998)
1997
T. Jeck, W.F. Riesen,
U. Keller		 Comparison of Bezafibrate and Simvastatin in the treatment of dyslipidaemia in patients with NIDDM Diabetic Medicine
14, 564-570 (1997)
W.F. Riesen Qualität im medizinischen Laboratorium Schweizer Spital
7, 25-27 (1997)
W. Haenggi, K. Lippuner,
W. Riesen, P. Jaeger,
M.H. Birkhäuser		 Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study British Journal of Obstetrics and Gynaecology
104, 708-717 (1997)
W. Korte Veno - occlusive disease of the liver after bone marrow transplantation: is hypercoagulability really part of the problem? Blood Coagulation Fibrinolysis
8, 367-381 (1997)
P. Ambühl, R. Wüthrich,
W. Korte, L. Schmid,
R. Krapf		 Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrology Dialysis Transplantation
12, 2355-2364 (1997)
P. Bovet, A. Rwebogora,
F. Perret, R. Darioli,
W. Riesen, F. Paccaud		 Differential relation between lifestyle variables and non-antiatherogenic and antiatherogenic HDL particles Can. J. Cardiol.
13 (Suppl. B), 96B-98B (1997)
Schweiz. Med. Wochenschrift
127 (Suppl. 88), 25S (1997)
1996
W.F. Riesen, H. Engler Clinical relevance of apolipoproteins Clinical Labaratory
42, 1-4 (1996)
T. Münzer, Ch. Heim,
W. Riesen		 Perioperativer Myokardinfarkt und weitere kardiale Komplikationen nach nichtkardialen Wahloperationen bei Patienten nach Myokardinfarkt. III: Troponin T - eine sinnvolle diagnostische Alternative beim perioperativen Myokardinfarkt? Anaesthesist
45, 225-230 (1996)
H. Engler, B. Thürlimann,
W.F. Riesen		 Biochemical markers of bone remodelling Onkologie
19, 126-131 (1996)
W. Korte, N. De Stoutz,
R. Morant		 Day to day titration with transdermal fentanyl in uncontrolled cancer pain: final results of a prospective study and long-term experiences in 39 patients Journal of Pain and Symptom Management
11, 139-146 (1996)
1995
H. Engler, W.F. Riesen Regulation of lipoprotein metabolism by thyroid hormones Advances in Lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. Proc. 8th Int. Dresden Lipid Symp. p. 291 (1995)
B. Waeber, P. Greminger,
W. Riesen, R. Darioli,
D. Simeon-Dubach,
R. Wunderlin		 Combined treatment with Captopril, Hydrochlorothiazide and Pravastatin in dyslipidemic hypertensive patients Blood Pressure
4, 358-362 (1995)
H. Engler, W.F. Riesen Lipoprotein(a) levels are influenced by thyroid function Bulletin of Molecular Biology and Medicine
20, 31-33 (1995)
W.F. Riesen Lipoproteinstoffwechsel und Thrombose Labor und Medizin
22, 12-16 (1995)
D.A. Tsakiris, W.F. Riesen, G.A. Marbet Lipoprotein(a) und Hämostase-Aktivierungsmarker bei Angina pectoris Deutsche med. Wochenschrift
120, 1109-1113 (1995)
W.F. Riesen, H. Engler Lp(a)-Serumwerte werden durch die Schilddrüsenfunktion beeinflusst Weller Verlag, M. Helmhold, V.W. Armstrong (Eds.), Risikofaktor
Lp(a)
114-119 (1995)
M. Lehnert, W.F. Riesen Früherkennung von Krebs mit Hilfe biochemischer Tumormarker Onkologie
18, 8-9 (1995)
W.F. Riesen Editorial Journal of Cardiovascular Pharmacology
25 (Suppl. 4) 1-2 (1995)
H. Engler, W. Riesen Pyridinium-Crosslinks: Sind die Resultate der freien PYD-, DPD-Bestimmung als Knochen-Resorptionsmarker vergleichbar zu denjenigen der Gesamt-PYD-, DPD-Konzentration? Klinisches Labor
41, 893-895 (1995)
U. Huber, L. Schmid Aktivierungsmarker der Gerinnung Labor und Medizin
22, 53-56 (1995)
W. Korte, C. Corbetta,
L. Schmid		 Ist die Bestimmung von Prothrombinfragmenten F1+2 zur Kontrolle der Heparintherapie bei Patienten mit tiefer Venenthrombose nützlich? Schweiz. Med. Wschr.
125, 420-423 (1995)
1994
H. Engler, W.F. Riesen,
B. Keller		 Anti thyroid peroxidase (anti TPO) antibodies in thyroid diseases, non-thyroidal illness and controls. Clinical validity of a new commercial method for detection of anti TPO (thyroid microsomal) auto antibodies. Clinica Chimica Acta
225, 123-136 (1994)
W. Korte, C. Baumgartner,
A. Feldges, C. Knöpfl, S. Lutz, A. Lenz, W. Riesen, L. Schmid		 Coincidence of familial platelet glycoprotein Ib/IX deficiency (Bernard-Soulier syndrome), idiopathic autoantibody against platelet, glycoprotein Ib/IX, familial appearence of antiphospholipid antibodies, and familial Factor XII deficiency Ann. Hematol.
68, 101-104 (1994)
F. Zanetti-Elshater,
R. Pingitore, C. Beretta-Piccoli, W. Riesen, G. Heinen		 Calcium antagonists for treatment of diabetes-associated hypertension: metabolic and renal effects of amlodipine. American Journal of Hypertension
7, 36-45 (1994)
P. Bovet, M. Rickenbach,
V. Wietlisbach, W. Riesen,
C. Shamlaye, R. Darioli,
B. Burnand		 Comparison of serum lipoprotein(a) distribution and its correlates among Black and White populations International Journal of Epidemiology
23, 20-27 (1994)
L.M. Böhlen, M. de Courten,
F. Hafezi, S. Shaw,
W. Riesen, P. Weidmann		 Insulin sensitivity and atrial natriuretic factor during -receptor modulation with Celiprolol in normal subjects Journal of Cardiovascular Pharmacology
23, 877-883 (1994)
B.M. Frey, R. Morant,
H.J. Senn, W.F. Riesen		 Clinical Assessment of the new tumor marker TPS Onkologie
17, 270-276 (1994)
M. Hoefliger, R. Morant,
W. Riesen, G. Baumgartner,
H. Engler		 CYFRA 21-1: erste Erfahrungen beim Bronchuskarzinom und anderen Tumoren Schweiz. Med. Wochenschrift
124, 1966-1970 (1994)
H. Engler, A. Lenz,
W.F. Riesen		 Bestimmung der Hydroxypyridinium-Crosslinks als Knochenabbau-Parameter mittels HPLC und Immunoassay Labor-Medizin
17, 256-259 (1994)
W.F. Riesen Trends und Entwicklung in der Tumordiagnostik: Zytokeratine als Tumor-assoziierte Marker Management & Krankenhaus
11, 46 (1994)
P.D. Zenobi (†), Y. Glatz,
A. Keller, S. Graf,
S.E. Jaeggi-Groisman,
W.F. Riesen, E.J. Schoenle, E.R. Froesch		 Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A European Journal of Endocrinology
131, 251-257 (1994)
R. Morant, L. Bacchus,
J. Meyer, W.F. Riesen		 Tumoranämie und Entzündungsmarker Schweiz. Med. Wochenschrift
124, 2267-2271 (1994)
W. Korte, A. Feldges Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution Clinical Investigator
72,
396-398 (1994)
W. Korte, A. Feldges,
C. Baumgartner, S. Ullmann, V. Niederer, L. Schmid		 Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report Klinische Pädiatrie
206, 331-333 (1994)
W. Korte, R. Morant Transdermal Fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding - a pilot study in 20 patients Supportive Care in Cancer
2, 123-127 (1994)
W. Korte, H. Otremba,
S. Lutz, R. Flury, L. Schmid,
M. Weissert		 Childhood stroke at three years of age with transient protein C deficiency, familial antiphospholipid antibodies and F. XII deficiency - a family study Neuropediatrics
25, 290-294 (1994)
P. Bovet, M. Rickenbach,
V. Wietlisbach, W. Riesen,
C. Shamlaye, R. Darioli,
B. Burnand		 Comparison of serum lipoprotein(a) distribution and its correlates among black and white populations Int. J. Epidemiol.
23 (1), 20-27 (1994)
1993
B. Burnand, V. Wietlisbach,
W. Riesen, G. Noseda,
F. Barazzoni, M. Rickenbach, F. Gutzwiller		 Lipides sanguins dans la population suisse: enquête MONICA 1988-89 Schweiz. med. Wochenschrift
123 (Suppl. 48), 29-37 (1993)
R. Morant, F. Stiefel,
W. Berchtold, A. Radziwill,
W. Riesen		 Preliminary results of a study assessing asthenia and related psychological and biological phenomena in patients with advanced cancer Supportive Care in Cancer
1, 101-107 (1993)
G.R. Warnick, G.J.M. Boerma, G. Assmann, A.T. Endler,
G. Gerique, A.M. Gotto,
M.S. Graziani, U. Lippi,
W. Patsch, W.F. Riesen,
E. Teng Leary, G. Hiller,
R. Zerback, R. Leinberger		 Multicenter evaluation of Reflotron direct dry-chemistry assay of high-density lipoprotein cholesterol in venous and fingerstick specimens Clinical Chemistry
39, 271-277 (1993)
P.D. Zenobi (†),
P. Holzmann, Y. Glatz,
W.F. Riesen, E.R. Froesch		 Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I Diabetologia
36, 465-469 (1993)
W.F. Riesen Fettstoffwechselstörungen nach Nierentransplantation TW Urologie Nephrologie
5, 383-388 (1993)
C.A. Carstensen, R. Nagel,
E. Knoll, H. Wisser,
G. Weidemann, W.F. Riesen, D. Seiler, D. Nagel		 Development and Evaluation of a reagent carrier with a new reaction sequence for the determination of creatinine in blood, plasma, serum and urine European Journal of Clinical Chemistry and Clinical Biochemistry
31, 335-346 (1993)
M. de Courten, P. Ferrari,
M. Schneider, L. Böhlen,
S. Shaw, W. Riesen,
G. Heynen, P. Weidmann		 Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension European Journal of Clinical Pharmacology
44, 457-462 (1993)
E. Suter, B. Marti, W. Riesen Körperfettverteilung: unabhängiger Einflussfaktor auf das Blutfettprofil Schweiz. Rundschau Med. (PRAXIS)
31, 807-812 (1993)
P. Ferrari, P. Weidmann,
W.F. Riesen, F. Martius,
S. Luban, E. Pasotti, P. Erne, C. Fragiacomo, G. Noseda,
F. Reutter, F.W. Amann,
R. Wunderlin		 Pravastatin zur Behandlung der primären Hypercholesterinämie: Schweizer Multizenter-Studie Schweiz. med. Wochenschrift
123, 1736-1741 (1993)
H. Engler, B. Keller, J. Halter, W.F. Riesen Assessment of thyroid function using different assay systems in thyroid disorders, non-thyroidal illness and euthyroid controls Klinisches Labor
39, 851-858 (1993)
W. Haenggi, W. Riesen,
M.H. Birkhaeuser		 Postmenopausal hormone replacement therapy with Tibolone decreases serum lipoprotein(a) European Journal of Clinical Chemistry and Clinical Biochemistry
31, 645-650 (1993)
W.F. Riesen, A. Lenz,
B. Keller, H. Engler		 Immunonephelometrische (INA) und immunoradiometrische (IRMA) Bestimmung von Lp(a) GIT Labor-Medizin
16, 236-237 (1993)
P. Bovet, B. Burnand,
L. Kappenberger, W. Riesen, R. Darioli		 Association entre lipoprotéine(a) et sténose des artères coronaires définie par angiographie Schweiz. med. Wochenschrift
123, 2138-2146 (1993)
H. Engler, W.F. Riesen Effect of thyroid function on concentrations of lipoprotein(a) Clinical Chemistry
39, 2466-2469 (1993)
W.F. Riesen, H. Keller Definition of the performance of tumor marker tests: principal considerations Journal of Tumor Marker Oncology
8, 15-20 (1993)
G. Noseda, W. Riesen Primäre Hyperlipoproteinämien Hadorn, Lehrbuch der Therapie, T. Hess, Herausg. p. 480-485. Hans Huber, Bern (1993)
E. Suter, B. Marti, W. Riesen Bedeutung der Lebensstilfaktoren für das Blutfettprofil von Bankangestellten. Soz. Präventivmed. Suppl. 2:
122-124 (1993)
W. Korte, G. Blatter,
J.-P. Ziegler,
C. Hanselmann, L. Schmid		 Kasabach-Merritt-Syndrom. Intraoperative Heparintherapie und spätere Kombinationstherapie mit Heparin und Ticlopidin zur Kontrolle der disseminierten intravasalen Gerinnung Deutsche med. Wochenschrift
118, 371-376 (1993)
W. Korte, J. Halter,
L. Schmid		 Juveniler Schlaganfall und Protein-S-Mangel Deutsche med. Wochenschrift
118, 1827 (1993)
1992
W.F. Riesen Neue Strategien in der Diagnose und Therapie von Hyperlipoproteinämien Schweiz. Rundschau Med. (PRAXIS)
81, 49-54 (1992)
W.F. Riesen Clinical Relevance of Lipoprotein Determination Klinisches Labor
38, 16-20 (1992)
Y. Allemann, S. Baumann,
M. Jost, P. Ferrari, S. Shaw,
W. Riesen, P. Weidmann		 Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril European Journal of Clinical Pharmacology
42, 275-280 (1992)
W.F. Riesen Der Lipidstoffwechsel und seine Störungen Schweiz. Apotheker-Zeitung
7, 192-196 (1992)
P. Ferrari, S. Shaw,
W. Riesen, P. Weidmann		 Plasma insulin during physiological and pathophysiological changes in atrial natriuretic factor European Journal of Clinical Pharmacology
42, 453-455 (1992)
W.F. Riesen, H. Keller Tumormarker - Ihre Bedeutung in Diagnostik und Therapie Der informierte Arzt
16, 1365-1373 (1992)
B. Marti, R. Malacrida,
S. Dai, M. De Grazia,
W.F. Riesen, T. Moccetti,
F. Gutzwiller		 Lipoproteins, apolipoproteins and life-style in 19-year-old men from Italian speaking Switzerland Nutrition, Metabolism and Cardiovascular Diseases
2, 178-184 (1992)
R. Mordasini, W. Riesen Medikamentöse Behandlung der Hyperlipoproteinämien Therapiewoche Schweiz
11, 795-804 (1992)
C. Ferrier, P. Ferrari,
P. Weidmann, U. Keller,
C. Beretta-Piccoli,
W.F. Riesen		 Swiss hypertension treatment programme with Verapamil and/or Enalapril in diabetic patients Drugs
44 (Suppl. 1), 74-84 (1992)
W.F. Riesen Diagnose und Therapie von Hyperlipoproteinämien Der Arzt und sein Patient (1992)
H. Engler, W.F. Riesen,
B. Keller		 Diagnostische Validität von Autoantikörpern gegen die mikrosomale Schilddrüsenperoxidase (anti-TPO) Schweiz. med. Wochenschrift
122, 1976-1980 (1992)
P.D. Zenobi (†),
S.E. Jaeggi-Groisman,
W.F. Riesen, M.E. Roder,
E.R. Froesch		 Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus Journal of Clinical Investigation
90, 2234-2241 (1992)
R. Laager, A.R. Miserez,
W.F. Riesen, T. Moccetti,
A. Del Bufalo, U. Keller		 Effect of Simvastatin on plasma lipoproteins, fibrinogen and glycaemic control in type II diabetic subjects Diabetic Research
21, 27-34 (1992)
W. Korte, R. Flury Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy Annals of Hematology
64, 152-154 (1992)
W. Korte, R. Flury, S. Lutz,
W.F. Riesen		 Vollautomatische PTT-Bestimmung - Vergleichbarkeit und Klinische Relevanz mit verschiedenen Reagenzien auf dem Gerinnungsanalysensystem Electra 1000C Labor-Medizin
15, 193-198 (1992)
1991
W.F. Riesen Lipoprotein(a) und koronare Herzkrankheit Gazette Médicale
1, 15-19 (1991)
W.F. Riesen Lipoprotein(a) - Bindeglied zwischen Fettstoffwechsel und Gerinnungssystem? Ärztl. Lab.
2, 31-36 (1991)
W.F. Riesen Sinnvolle Analyse von Fettstoffwechselstörungen in der Praxis Ars Medici
3, 124-130 (1991)
W.F. Riesen Lipoprotein(a) - Bindeglied zwischen Fettstoffwechsel und Gerinnung? Z. med. Lab.diagn.
32, 147-149 (1991)
W.F. Riesen, R. Mordasini Hypercholesterinaemie - Sinnvolle Abklärung und Behandlung Hospitalis
61, 242-248 (1991)
P. Ferrari, Y. Alleman,
S. Shaw, W. Riesen,
P. Weidmann		 Reproducibility of insulin activity measured by the minimal model method Diabetologia
34, 527-530 (1991)
U. Keller, C. Wackernagel,
C. Messer, W. Riesen		 Vergleich einer kalorien-definierten Diät mit der konventionellen Austauschdiät bei Diabetes mellitus Typ 2 Schweiz. med. Wochenschrift
121, 1014-1019 (1991)
J.J. Brocard, U. Keller,
A. Oberhänsli, W.F. Riesen		 Wirkungen und Nebenwirkungen einer einjährigen Behandlung der primären Hypercholesterinämie mit Simvastatin Schweiz. med. Wochenschrift
121, 977-983 (1991)
W.F. Riesen Diagnostic value of several lipoprotein constituents for CHD risk estimation Int. Symp. Lipid, Dresden (1991)
W.F. Riesen Lipoprotein(a) - Bindeglied zwischen Fettstoffwechsel und Gerinnungssystem? Schweiz. med. Wochenschrift
121, 1813-1818 (1991)
B.N. Trost, W.F. Riesen,
R.C. Mordasini,
P. Weidmann		 Antihypertensive long-term monotherapy with the calcium antagonist nitrendipine does not alter serum lipids in type II diabetic patients Nutrition, Metabolism and Cardiovascular Diseases
1, 77-81 (1991)
C. Ferrier, P. Ferrari,
P. Weidmann, U. Keller,
C. Beretta-Piccoli,
W.F. Riesen		 Antihypertensive Therapy With Ca2+. Antagonist Verapamil and/or ACE Inhibitor Enalapril in NIDDM Patients Diabetes Care
10, 911-914 (1991)
P. Ferrari, J. Rosman,
N. Newner, S. Shaw,
W. Riesen, P. Weidmann		 Postsynaptic alpha-1-blockade with Teratosin does not modify insulin sensitivity in nonobese normotensive subjects Journal of Cardiovascular Pharmacology
18, 106-110 (1991)
P. Bovet, C. Shamlaye,
A. Kitua, W.F. Riesen,
F. Paccaud, R. Darioli		 High prevalence of cariovascular risk factors in the Seychelles (Indian Ocean) Arteriosclerosis and Thrombosis
11, 1730-1736 (1991)
P. Ferrari, P. Weidmann,
S. Shaw, D. Giachino,
W. Riesen, Y. Allemann,
G. Heynen		 Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensive parent American Journal of Medicine
91, 589-596 (1991)
P. Ferrari, D. Giachino,
P. Weidmann, S. Shaw,
W. Riesen, N. Neuner,
U. Keller, G. Heynen		 Unaltered insulin sensitivity during calcium channel blockade with amlodipine European Journal of Clinical Pharmacology
41, 109-113 (1991)
1990
W.F. Riesen, U. Keller,
R. Stohler, E. Pasotti,
A. del Bufalo, T. Moccetti,
O. Bertel, F.W. Reutter		 Effect of Simvastatin Therapy on Apolipoproteins Drug Investigation
2 (Suppl. 2), 48-52 (1990)
H. Keller, W.F. Riesen Zur Bestimmung der Apolipoproteine Apo A-I und Apo B. Eine Studie zum Methodenvergleich. Z. med. Lab. diagn.
31, 200-210 (1990)
W.F. Riesen Laboratory diagnosis of hypercholesterolemia and its traps European Journal of Internal Medicine
1, 253-258 (1990)
F. Buser, W.F. Riesen,
R. Mordasini		 Lipid Screening in Paediatrics for Early Detection of Cardio vascular Risks J. Clin. Chem. Clin. Biochem.
28, 107-111 (1990)
W.F. Riesen Experience with Low-Density Lipoprotein Apheresis by Polyclonal and Monoclonal Anti-Apolipoprotein B Antibodies and by Dextran Sulfate Cellulose Curr. Stud. Hematol. Blood Transf.
57, 208-219 (1990)
W. Riesen, J. Flückiger Vergleichbarkeit oder Übereinstimmung? Zur Bestimmung der Apolipo-proteine A-I und B - Ein Methodenvergleich Bulletin SGKC
31/1, 10-27 (1990)
B. Marti, E. Suter,
W.F. Riesen, A. Tschopp,
H.-U. Wanner, F. Gutzwiller		 Effects of long-term,self-monitored exercise on the serum lipoprotein and apolipoprotein profile in middle-aged men Atherosclerosis
81, 19-31 (1990)
W. Riesen, H. Keller Zur Methodik der Cholesterinbestimmung: konventionelle Verfahren oder "Trockenchemie"? Therapeutische Umschau
47, 456-466 (1990)
H. Saxenhofer,
P. Weidmann, W.F. Riesen,
C. Beretta-Piccoli,
C. Fragiacomo,
R. Wunderlin, G. Noseda		 Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipo-proteinaemia type II European Journal of Clinical Pharmacology
39, 101-105 (1990)
P. Weidmann, D.C. Schohn,
W. Riesen, H.A. Jahn,
P. Ferrari, S.G. Shaw,
C. Beretta-Piccoli		 Association Between Sympathetic Activity and the Atherogenic Serum Cholesterol Fraction European Journal of Clinical Pharmacology
39, 101-105 (1990)
B. Marti, M. Knobloch,
W.F. Riesen, H. Howald		 Fifteen-year changes in exercise, aerobic power, abdominal fat, and serum lipids in runners and controls Medicine and Science in Sports and Exercise
23, 115-122 (1990)
W.F. Riesen Biochemie und Pathobiochemie des Fettstoffwechsels Mitteil. der Arbeitsgem. Klin. Nephrologie
19, 20-30 (1990)
W.F. Riesen Wie zuverlässig ist die Reflotron-HDL-Cholesterin-Methode? Schweiz. med. Wochenschrift
120, 1971-1975 (1990)
W.F. Riesen Extrakorporale Elimination atherogener Lipoproteine (LDL-Apherese) Therapiewoche Schweiz
6, 12, 986-995 (1990)